Yatharth Hospital: CCI clears Advent's Rs 3,150 crore investment for 24.9%

The Competition Commission of India (CCI) on Tuesday, 10 November 2026 approved Advent International's proposed investment in Yatharth Hospital & Trauma Care Services Ltd, the north India hospital chain. The private equity firm is putting Rs 3,150 crore of fresh capital into the company through its affiliate Rasmalai Limited, by subscribing to equity shares and warrants that would give it about 24.9% of Yatharth on full conversion. The competition regulator named Rasmalai Limited as the acquirer and said it is indirectly controlled by funds managed or advised by Advent. The deal was first announced on 17 September 2026 and still needed regulatory approvals.

India's private hospital sector has become one of the busiest areas for global private equity, because demand for hospital beds keeps rising faster than supply, especially outside the biggest metros. Yatharth is a mid-sized, listed chain focused on north India, and Advent's money is meant to let it grow quickly by buying other hospitals rather than only building new ones, which takes years.

The structure matters too. Because the Rs 3,150 crore is primary capital, it goes into Yatharth's own accounts to fund expansion, instead of paying out existing owners. And because Advent's stake is set at about 24.9%, it sits just below one quarter of the company, while the founding family keeps the largest holding. Reports of the deal did not mention an open offer to other shareholders.

The CCI's approval removes one of the main regulatory steps. The regulator reviews deals above set size limits to check that they will not harm competition. The commission announced its approval of the proposed acquisition on 10 November and said a detailed order would follow.

For patients and staff in the regions Yatharth serves, the practical question is what the expansion brings: more beds, more specialities and possibly new hospitals in towns where good tertiary care is scarce. For the healthcare industry, the deal is another sign that large global investors see India's mid-sized hospital chains as a growth story.

Peepals calculation: Rs 3,150 crore for about 24.9% of the company implies a post-deal value for the whole of Yatharth's equity of roughly Rs 12,650 crore (3,150 ÷ 0.249 = 12,651). Going from about 2,800 beds to more than 5,000 would mean at least 2,200 more beds, a rise of about 79% (5,000 ÷ 2,800 = 1.79). If all of Advent's money went to that growth, it would equal about Rs 1.4 crore per added bed (3,150 ÷ 2,200 = 1.43); this is only a ratio, since the company will also spend on upgrades. Our calculation from the reported figures.

Short-term: With the CCI's approval in hand, Yatharth can move towards completing the share and warrant issue to Rasmalai Limited, subject to any remaining approvals. The fresh money strengthens its balance sheet for acquisitions.

Long-term: If the expansion goes to plan, Yatharth could nearly double its bed count, add hospitals in new north Indian cities and compete harder with larger chains. Advent, which has invested in Indian healthcare before, gains a significant minority position in a growing listed hospital group.

Who is affected: Yatharth's shareholders, doctors and staff, patients in its catchment areas, rival hospital chains in north India, and hospital owners who may become acquisition targets.

Questions and Answers